Top-line Results to be Released as a Late-Breaking Presentation
SAN DIEGO, Oct. 16, 2018 (GLOBE NEWSWIRE) — Samumed, LLC, announced today that data will be presented from a phase 2b trial of its small molecule Wnt pathway inhibitor, SM04690, in development as a potential DMOAD, for the treatment of knee osteoarthritis (OA). These data were accepted as a late-breaking poster presentation at the upcoming 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting, October 19-24, 2018, in Chicago.
Samumed will also present two additional posters showing SM04690 clinical data and an oral presentation showing preclinical data on SM04755, a topical Wnt pathway inhibitor currently being developed for the treatment of tendinopathy. The company will also sponsor an Innovation Theater entitled “Osteoarthritis vs. Rheumatoid Arthritis: Parallels, Pathways, & Paradigms.” This program will be chaired by world renowned faculty, including Dr. Vibeke Strand, Clinical Rheumatologist and Consultant, Clinical Research and Regulatory Affairs, Portola Valley, CA, Dr. Rik Lories, Professor of Rheumatology, Skeletal Biology and Engineering Research Center, KU Leuven, Belgium and Dr. Yusuf Yazici, Chief Medical Officer of Samumed.
“We are pleased to have the opportunity to present initial data from our phase 2b study of SM04690, in development as a potential DMOAD, for the treatment of knee OA. Given all of the important advances in the field of rheumatology, it is an honor to be accepted in the late-breaker session at this year’s ACR/ARHP Annual Meeting,” said Dr. Yazici.
Oral presentation details:
| Abstract Title | Date/Time | Session Title |
| Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway Abstract Number #1952 |
Monday, Oct. 22 4:30 – 6:00 p.m. CDT |
4M114 ACR/ARHP Abstract: Orthopedics, Low Back Pain & Rehabilitation (1952–1957) |
Poster presentation details:
| Abstract Title | Date/Time | Session Title |
| Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor Abstract Number #1364 |
Monday, Oct. 22 9:00 – 11:00 a.m. CDT |
Osteoarthritis – Clinical Poster II |
| Assessment of Health-Related Quality of Life in a 52-Week, Phase 2, Randomized, Controlled Trial of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Treatment of Knee Osteoarthritis Abstract Number #1366 |
Monday, Oct. 22 9:00 – 11:00 a.m. CDT |
Osteoarthritis – Clinical Poster II |
| Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee Abstract Number #L03 |
Tuesday, Oct. 23 9:00 – 11:00 a.m. CDT |
Late-Breaking Abstract Poster Session |
Innovation Theater details:
| Presentation Title | Date/Time | Session Title |
| Osteoarthritis vs. Rheumatoid Arthritis: Parallels, Pathways, & Paradigms | Monday, Oct. 22 2:30 p.m. CDT |
Innovation Theater – Hall A |
Further details can be found on the ACR website at https://www.rheumatology.org/Annual-Meeting. A copy of the presentation materials can be accessed by visiting the Publications section of the Samumed website following the conclusion of the presentations.
About the American College of Rheumatology (ACR) Annual Meeting
The American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting is the largest rheumatology meeting in the world and the premier educational event for physicians, healthcare professionals and scientists who treat or research rheumatic and musculoskeletal diseases. It is attended by more than 15,000 rheumatology professionals from over 100 countries.
About SM04690
SM04690 is a small molecule inhibitor of the Wnt pathway administered as an intra-articular injection and is being developed as a potential disease modifying drug for osteoarthritis (DMOAD). Vehicle-controlled preclinical data suggested that SM04690 has a dual mechanism of action with three effects on joint health – generation of cartilage, slowing down of cartilage breakdown, and reduction of inflammation. There are currently no approved disease modifying treatments for osteoarthritis. Additional information on Samumed’s SM04690 osteoarthritis program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=20.
About SM04755
SM04755 is a small molecule Wnt pathway inhibitor and is being developed as a potential topical therapy for the treatment of tendinopathy. Preclinical data suggested that, compared to controls, SM04755 inhibited inflammation, reduced fibrosis, and improved rates of tendon repair. Additional information on Samumed’s SM04755 tendinopathy program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=13.
About Samumed
Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Learn more about Samumed’s potential regenerative drug candidates and broad clinical pipeline at https://www.samumed.com/pipeline/default.aspx.
Corporate Contact:
Erich Horsley
Samumed, LLC
erich@samumed.com
858-365-0200
Investor Contact:
Ashley Robinson
LifeSci Advisors
arr@lifesciadvisors.com
617-535-7742
Media Contact:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
jo@lifescipublicrelations.com
646-751-4361
